

#28/7R.

11/30/98

SP 1645

Docket No. 732250-198

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICATION OF: KNIPE, ET AL.

SERIAL NO: 08/278,601

GROUP ART UNIT: 1645

FILED: July 21, 1994

EXAMINER: Caputa, A.

FOR: HERPESVIRUS REPLICATION EFFECTIVE MUTANTS

RECEIVED
TOSH CENTER 11/30/98
58 NOV 20 PM 2:15Assistant Commissioner of Patents and Trademarks
Washington, DC 20231

SIR:

Pursuant to 37 C.F.R. §1.56(a), Applicant(s) hereby cite(s) the enclosed documents listed on the attached copy of Form PTO-1449 which are believed to be material to the patentability of the above-identified application.

This Supplemental Information Disclosure Statement is filed in accordance with the paragraph of 37 CFR §1.97 indicated below:

___ §1.97(b) This Information Disclosure Statement is filed:

- (1) Within three months of the filing date of a national application; OR
- (2) Within three months of the date of entry of the national stage of an international application; OR
- (3) Before the mailing of a first Office Action on the merits.
No fee or statement is required.

___ §1.97(c) This Information Disclosure Statement is filed after the period specified in paragraph (b) above, but before the mailing date of either:

- (1) A Final Action or under 37 CFR §1.113; OR
- (2) A Notice of Allowance under 37 CFR §1.311; AND

is accompanied by either: (check one)

___ The statement as specified in 37 CFR §1.97(e) set out below;
OR

___ The fee of \$240.00 under 37 CFR §1.17(p).

11/19/1998 TLW11 00000080 08278601

01 FC:122

130.00 OP

x §1.97(d) This Information Disclosure Statement is filed after the mailing date of either:

- (1) a Final Action or under 37 CFR §1.113; OR
- (2) A Notice of Allowance under 37 CFR §1.311;

BUT filed on or before payment of the Issue Fee; AND
is accompanied by:

- (1) The statement as specified in 37 CFR §1.97(e) as set forth below; AND
- (2) Petition is hereby made under 37 CFR §1.97(d) for consideration of this Information Disclosure Statement; AND,
- (3) The petition fee of \$130.00 set out in 37 CFR §1.17(i).


 X §1.97(e) The undersigned Attorney hereby states that:

 X each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of this Information Disclosure Statement;

or

 no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, or to the knowledge of the undersigned Attorney after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing date of the Information Disclosure Statement.

The Commissioner is authorized to charge payment of any fees associated with this communication or credit any overpayment to Deposit Account No. 03-0678.

FIRST CLASS CERTIFICATE	
I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as First Class Mail in an envelope addressed to:	
Assistant Commissioner for Patents Washington, DC 20231	
 Raina Semionow, Esq.	November 10, 1998 Date

Respectfully submitted,



Raina Semionow, Esq.
Reg. No. 39,022
CARELLA, BYRNE BAIN, GILFILLAN,
CECCHI, STEWART & OLSTEIN
Six Becker Farm Road
Roseland, NJ 07068
Tel: (973)994-1700
Fax: (973)994-1744

RECEIVED
FBI CENTER 1600/2909
98 NOV 20 PM 2:15